Evidence map›Paper›PMID 21191076›Full record

Trial reportClinical and vaccine immunology : CVI2011

Safety and immunogenicity of coadministering a combined meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine with 7-valent pneumococcal conjugate vaccine and measles, mumps, and rubella vaccine at 12 months of age.

Elizabeth Miller, Nick Andrews, Pauline Waight, Helen Findlow, Lindsey Ashton, Anna England, Elaine Stanford, Mary Matheson, Joanna Southern, Elizabeth Sheasby and 2 more

2 registry-linked trialsOpen access · diamondAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical and vaccine immunology : CVI, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00625677 phase4completednot on this map

A Phase IV, Randomized Study to Evaluate the Immune Response of UK Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life

TypeinterventionalSponsorPublic Health EnglandRan2008 to 2010Enrolled130ConditionsMeningococcal Infections, Pneumococcal InfectionsArmsNeisVacC (Meningococcal C conjugate vaccine), Menjugate (Meningococcal C conjugate vaccine)
NCT04056117 phase1 / phase2completednot on this mapstarted 2019, after this paper: background citation

Safety and Immunogenicity of a Shigella-Tetravalent Bioconjugate Vaccine: A Phase 1/2 Randomized Controlled and Age Descending Study Including Dose Finding in 9 Month Old Infants

TypeinterventionalSponsorLimmaTech Biologics AGRan2019 to 2022Enrolled597ConditionsShigellosisArmsShigella 4V, MenACWY, Rabies, Diphtheria, Tetanus and Pertussis (DTaP), Placebo
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Review
  4. Article
  5. Interactions of conjugate vaccines and co-administered vaccines.Human vaccines & immunotherapeutics · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Elizabeth MillerImmunisation, Hepatitis and Blood Safety Department, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom.
Nick Andrews
Pauline Waight
Helen Findlow
Lindsey Ashton
Anna England
Elaine Stanford
Mary Matheson
Joanna Southern
Elizabeth Sheasby
David Goldblatt
Ray Borrow
Manchester Royal Infirmary · GBUniversity College London · GBUniversity of Manchester · GB

Funding

Department of Health 039/031
6 · The paper itself

Abstract

The coadministration of the combined meningococcal serogroup C conjugate (MCC)/Haemophilus influenzae type b (Hib) vaccine with pneumococcal conjugate vaccine (PCV7) and measles, mumps, and rubella (MMR) vaccine at 12 months of age was investigated to assess the safety and immunogenicity of this regimen compared with separate administration of the conjugate vaccines. Children were randomized to receive MCC/Hib vaccine alone followed 1 month later by PCV7 with MMR vaccine or to receive all three vaccines concomitantly. Immunogenicity endpoints were MCC serum bactericidal antibody (SBA) titers of ≥8, Hib-polyribosylribitol phosphate (PRP) IgG antibody concentrations of ≥0.15 μg/ml, PCV serotype-specific IgG concentrations of ≥0.35 μg/ml, measles and mumps IgG concentrations of >120 arbitrary units (AU)/ml, and rubella IgG concentrations of ≥11 AU/ml. For safety assessment, the proportions of children with erythema, swelling, or tenderness at site of injection or fever or other systemic symptoms for 7 days after immunization were compared between regimens. No adverse consequences for either safety or immunogenicity were demonstrated when MCC/Hib vaccine was given concomitantly with PCV and MMR vaccine at 12 months of age or separately at 12 and 13 months of age. Any small differences in immunogenicity were largely in the direction of a higher response when all three vaccines were given concomitantly. For systemic symptoms, there was no evidence of an additive effect; rather, any differences between schedules showed benefit from the concomitant administration of all three vaccines, such as lower overall proportions with postvaccination fevers. The United Kingdom infant immunization schedule now recommends that these three vaccines may be offered at one visit at between 12 and 13 months of age.

Indexed as

Antibodies, BacterialHaemophilus VaccinesHeptavalent Pneumococcal Conjugate VaccineHumansImmunization ScheduleImmunization, SecondaryImmunoglobulin GInfantMeasles-Mumps-Rubella VaccineMeningococcal VaccinesPneumococcal VaccinesUnited KingdomVaccinationAntibodies, BacterialHaemophilus VaccinesHeptavalent Pneumococcal Conjugate VaccineImmunoglobulin GMeasles-Mumps-Rubella VaccineMeningococcal VaccinesPneumococcal Vaccines

Identifiers

PMID21191076
PMCPMC3067384
OpenAlexW2113049111

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.